Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis.
Obstructive coronary artery disease is the most common cause of morbidity and mortality in the developed world. Our understanding of the pathobiology of coronary atherosclerosis provides us with new opportunities to reduce myocardial ischemia by interventions that address these mechanisms directly. These interventions include lipid-lowering therapies that improve local coronary vasomotion, inflammation, and the procoagulant state. These interventions have also been shown to result in important reductions in clinical events, including angina pectoris, myocardial ischemia and infarction, and death. Ambulatory electrocardiography provides a versatile and quantifiable measure of regional myocardial ischemia. Reductions in ischemia, as quantified by this diagnostic modality, are associated with improved clinical outcomes that may reflect improvements in the cellular pathophysiology of coronary atherosclerosis. This review discusses new information regarding the interactions between low-density lipoprotein cholesterol, the cell biology of atherosclerosis, and the activity of ischemia in patients with coronary artery disease.
Orford
J L
JL
Cardiac Catheterization Laboratory Office L2-296, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Kinlay
S
S
Ganz
P
P
Selwyn
A P
AP
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000150:complications / Q000503:physiopathology*; D015716:Electrocardiography, Ambulatory; D004730:Endothelium, Vascular / Q000503:physiopathology; D006801:Humans; D008148:Lovastatin / Q000627:therapeutic use; D008297:Male; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D012307:Risk Factors
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D008148:Lovastatin